90% cuts at Renovo as Shire ends Juvista deal
This article was originally published in Scrip
Executive Summary
Shire has terminated its licensing deal with Renovo for the wound-healing product Juvista, following the recent failure of the drug in Phase III trials. Renovo will now cut 100 of its 110 staff, including members of its board, and is "exploring all options to maximise shareholder value".
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.